Tracking the PRTA option chain helps you see every strike and expiry on Prothena Corp Plc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Prothena Corp Plc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of PRTA options activity at a glance. Use our scanner to monitor the PRTA option chain in real time and filter for the PRTA options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For PRTA stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the PRTA option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where PRTA stock options are being actively traded and where they are not.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Prothena Corp Plc's full chain across every expiry, highlights the most liquid strikes, and lets you screen PRTA options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of PRTA stock options — let the full option chain come to you, pre-filtered and ready to trade.
